University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 5GYN-13-1


The MILO Study (MEK Inhibitor in Low-Grade Serous Ovarian Cancer): A Multi-National, Randomized, Open-Label Phase III Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Type: Cancer Therapy
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Agustin Garcia, M.D.
Other Trial Staff:  Kristy Watkins, R.N., Grace Facio, R.N., Yvonne Flores, D.M., Yanli Wang, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.